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        Macrophage activation profi  les 
and NF-    B 
  Infl  ammation is at once physiological 
and pathophysiologic. As an essential 
response to harmful stimuli such as 
chemical injury and microbial patho-
gens, infl  ammatory activation must be 
tightly coupled with regulatory mech-
anisms that bring about its own resolu-
tion. If these regulatory mechanisms fail, 
sustained collateral damage to healthy 
cells and tissues ensues. Persistent and 
aberrant infl  ammation plays a role in 
many, if not most, serious human dis-
eases including atherosclerosis, auto-
immune disorders, neurodegenerative 
disease, obesity/diabetes, chronic infec-
tion, and cancer. 
  Macrophages comprise a diverse 
cell lineage that manifests its biological 
activities in tissue-, diff  erentiation 
state  –  , and stimulus-specifi  c  contexts. 
Multifunctional by nature, macro-
phages can directly eff  ect microbial or 
tumor cell killing, can release chemo-
kines and cytokines to amplify acute 
infl  ammation, and can present antigens 
to stimulate adaptive immunity. If in-
fl  ammation is likened to an orchestral 
symphony  —  one that can be performed 
to virtuosity (disease resolved) or ca-
cophony (disease aggravated)  —  then 
the macrophage, with its potential to 
exert a broad range of proinfl  ammatory 
and/or antiinfl  ammatory activities, is 
the conductor. 
  Macrophage activation can be di-
vided into two modes, according to a 
useful classifi   cation scheme that has 
emerged in recent years (  1, 2  ). Classical 
macrophage activation (M1), which is 
essentially proinfl  ammatory, can be in-
duced by interferon (IFN)-      and trig-
gers the release of interleukin (IL)-12, 
the induction of nitric oxide (NO) 
synthase 2 (NOS2), and the up-regula-
tion of major histocompatibility com-
plex (MHC) class II expression. M1 
macrophages are thought to play a key 
role in the phagocytic killing of mi-
crobes and the initiation of humoral 
immunity. Alternative macrophage ac-
tivation (M2), by contrast, results in an 
antiinfl   ammatory phenotype. Alterna-
tive activation is driven by IL-4 and IL-
13 and yields macrophages that express 
lower levels of MHC class II and pro-
duce less IL-12 and NO. Decreased 
NO production results from a STAT-
6  –  dependent, arginase-mediated deple-
tion of arginine, the substrate for the 
NO-generating enzyme NOS2 (  3  ). M2 
macrophages produce higher levels of 
antiinfl  ammatory factors such as IL-10, 
and are thought to play a primary role 
in the resolution of infl  ammation and 
the coordination of tissue repair after 
the acute infl  ammatory reaction. 
  The ubiquitous family of heterodi-
meric NF-     B transcriptional regulators 
coordinates responses to exogenous 
stress that aff  ect cell activation, prolifera-
tion, and survival (  4, 5  ). Consequently, 
NF-     B is a pivotal player in infl  amma-
tory processes during immune responses 
and cancer (  6, 7  ). However, the in-
volvement of NF-     B signaling path-
ways in the development of M1 versus 
M2 macrophage activation is poorly un-
derstood. Several years ago, NF-     B was 
shown to be active in macrophages not 
only during the induction of infl  amma-
tion, wherein it primarily drives pro-
infl  ammatory gene activation, but also 
during the resolution of infl  ammation, 
wherein it preferentially drives antiin-
fl  ammatory gene activation and the in-
duction of macrophage apoptosis (  8  ). 
  At baseline, NF-     B is kept inactive 
through the action of I     B. When extra-
cellular signals (e.g., pathogen-associ-
ated molecular patterns) engage specifi  c 
integral membrane receptors (e.g., Toll-
like receptors [TLRs]), IKK enzymes 
phosphorylate I     B leading to its ubiq-
uitination and eventual degradation, 
thus freeing NF-     B to enter the nucleus 
and activate gene expression (  9  ). IKK     , a 
subunit of the IKK complex, is a well-
recognized activator of NF-     B and con-
sequent target for NF-     B inhibition. 
Two studies in this issue, by Hagemann 
et al. (  10  ) on page 1261 and Fong 
et al. (  11  ) on page 1269, provide novel 
insights into how IKK     /NF-     B regu-
lates macrophage activation profi  les in 
the context of cancer and resistance to 
acute infection. 
  IKK     and immunosuppression 
of tumor-associated macrophages 
(TAMs) 
  Although M1 macrophages have the in-
trinsic ability to kill cancer cells (  1  ), 
TAMs are typically polarized to the M2 
phenotype in terms of their cytokine 
production profi  le (  12  ). The culprit of 
this altered macrophage phenotype is 
likely the tumor itself, as co-culture with 
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lator in limiting macrophage activation 
and promoting the resolution of infl  am-
mation during certain infections. Previ-
ous work has shown that the other IKK 
catalytic subunit, IKK     , suppresses NF-
     B activation by accelerating the turn-
over of NF-     B subunits RelA and 
c-Rel and thus their removal from pro-
infl  ammatory gene promoters. Consis-
tently, inactivation of IKK      in mice led 
to enhanced infl  ammation and bacterial 
clearance (  19  ). One obvious implica-
tion of these studies is that our immune 
capacity for bacterial eradication is per-
haps not as good as it could be due 
to counterbalancing mechanisms that 
limit tissue injury and resolve infl  am-
mation. A more sinister implication is 
that certain microbial pathogens, in a 
fashion analogous to tumor cells, have 
evolved mechanisms to manipulate NF-
     B signaling pathways and thus skew 
macrophage activation toward a more 
immunosuppressive phenotype, which 
facilitates their survival within the host. 
  Therapeutic manipulation 
of macrophages through IKK     
inhibition? 
  Developing eff   ective therapies against 
cancer poses one of the greatest chal-
lenges to human medicine. Besides the 
nonspecifi  city of many cytotoxic anti-
cancer regimens, the abnormal and un-
stable genome of cancer cells may 
promote the development of intrinsic 
and acquired resistance mechanisms that 
render the tumor refractory to chemo-
therapy (  20  ). Similarly, the capacity of 
microorganisms to evolve drug resis-
tance, which has been amply demon-
strated since the introduction of 
antibiotics seven decades ago, compro-
mises treatment of infections world-
wide, a fact illustrated by the current 
epidemics of multidrug-resistant   Staph-
ylococcus aureus   and   Mycobacterium tuber-
culosis   (  21  ). These realities beg the 
question of whether the tumor cell or 
the pathogen is ultimately sustainable as 
the principle target of therapy. The new 
studies by Hagemann et al. and Fong 
et al. defi  ne a novel role for IKK      in 
promoting M2 macrophage activation, 
away from the M1 phenotype that is 
optimal for clearance of bacteria and 
infections. This group used Cre/ lox   gene 
targeting to delete IKK      in either mye-
loid lineage cells (macrophages and neu-
trophils) or airway epithelial cells. The 
resulting mice had surprisingly diff  erent 
responses to an infectious challenge de-
pending on the cell type that lacked 
IKK     . In a bacterial pneumonia model, 
clearance of group B   Streptococcus   (GBS) 
and neutrophil recruitment to the site of 
infection were decreased in mice with 
IKK     -defi  cient airway epithelia as com-
pared with littermate controls. In marked 
contrast, neutrophil recruitment and 
clearance of GBS were enhanced in 
mice with IKK     -defi  cient myeloid cells, 
rendering these mice more resistant to 
pneumonia and lethal systemic GBS 
infection. The IKK     -null macrophages 
had increased expression of IL-12, 
NOS2, and MHC class II and decreased 
expression of IL-10 and arginase 1, con-
sistent with a proinfl  ammatory M1 phe-
notype. Biochemical analyses suggested 
that IKK      normally inhibits STAT-1 
activation, which is required for respon-
siveness to IFN-     and thus the M1 mode 
of macrophage activation (  Fig. 1  ). 
  The precise mechanisms underlying 
the enhanced immunity seen in mice 
lacking IKK      in myeloid cells remain 
unclear, as statistically signifi  cant  dif-
ferences in direct killing of GBS by 
macrophages or neutrophils were not 
observed in vitro (  11  ). NO is not eff  ec-
tively bactericidal against GBS, nor is it 
required for GBS killing by macro-
phages (  17  ); however, inhibition of 
NO production by aminoguanidine in-
creased mortality in a GBS sepsis model 
(  18  ). It is thus likely that NO plays an 
indirect, proinfl  ammatory role in stim-
ulating the enhanced antibacterial de-
fense demonstrated in the study by Fong 
et al. The authors  ’   fi  ndings are not spe-
cifi  c to GBS, as macrophages from mice 
with IKK     -defi  cient myeloid cells also 
resisted the characteristic switch to an 
M2 phenotype in response to   Cryptococ-
cus neoformans   infection. The mice were 
consequently better able to recruit T 
cells and resolve the infection. 
  These observations suggest that the 
outcome of IKK      activation during in-
fection is tissue specifi   c, and reveal a 
previously unknown role for this regu-
ovarian cancer cells promotes macro-
phage diff  erentiation toward the M2 
profi  le (  13  ). Signals from the TAMs in 
turn promote tumor cell migration, in-
vasiveness, and metastasis (  14  ). The de-
pendency of cancers on this alliance with 
M2-type macrophages is exemplifi  ed by 
experimental mammary tumor models. 
In these models, increased macrophage 
infi  ltration promotes the development 
of a supportive vasculature and malig-
nant conversion of the tumor (  15  ), 
whereas reducing macrophage infi  ltration 
by blocking chemokine receptors in-
hibits tumor growth (  16  ). 
  The study by Hagemann et al. (  10  ) 
dissects the relationship between NF-     B 
signaling and the immunosuppressive 
M2 phenotype of TAMs. Using bio-
luminescent tumor imaging, the authors 
assessed how selective inhibition of 
IKK      (and hence NF-     B) in macro-
phages aff  ects cancer progression in vivo. 
Macrophages (bone marrow derived or 
isolated from an established tumor site) 
transfected with a dominant-negative 
IKK      construct decreased tumor bur-
den when transferred into tumor-bear-
ing mice. This protection was associated 
with an M2-to-M1 switch in the profi  le 
of the cells and increased STAT-1 acti-
vation, which is critical for the produc-
tion of IL-12 and NO. Some of the 
antitumor activity of IKK     -defi  cient 
TAMs might be explained by increased 
NOS2 expression. However, IL-12  –
  mediated recruitment of natural killer 
(NK) cells into the tumor was found to 
be critical for tumor regression, as block-
ing IL-12 in the mice that received 
IKK     -defi  cient macrophages reduced 
NK recruitment and restored the rate of 
tumor growth to that seen in control 
mice. This study is the fi  rst to identify 
NF-     B signaling as a central mechanism 
in maintaining the immunosuppressive 
phenotype of TAMs. 
  Tissue-specifi  c roles for IKK     during 
the infl  ammatory response 
to acute infection 
  The contributions of IKK     /NF-     B to 
the classical versus alternative modes of 
macrophage activation are further ex-
plored by Fong et al. (  11  ) in the context 
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impair the antibacterial program medi-
ated by epithelial cells. TLR-mediated 
recognition of pathogen associate mo-
lecular patterns leads to NF-     B  –  de-
pendent activation of proinfl  ammatory 
genes, and this response is essential for 
defense against infectious organisms. Yet, 
IKK      also has important antiinfl  amma-
tory roles because targeted deletion of 
IKK      in myeloid cells, or its prolonged 
pharmacologic blockade, enhances sus-
ceptibility of mice to endotoxin-medi-
ated shock by releasing NF-    B  –  mediated 
inhibition of IL-1      production (  25  ). 
Moreover, rare inherited immunodefi  -
ciencies associated with aberrant NF-     B 
signaling have been described, but to 
date, mutations have been found only in 
the regulatory subunit IKK     /NEMO, 
mouse model of colitis-associated can-
cer, for example, deletion of IKK      in 
either colonic epithelial cells or in lamina 
propria macrophages led to a striking de-
cline in tumor load (  23  ). And whereas 
deletion of IKK      in liver cells alone in-
creased sensitivity to chemically induced 
hepatocellular carcinoma (HCC), simul-
taneous deletion of IKK      in both hepa-
tocytes and infi  ltrating  macrophages 
dramatically reduced the size and num-
ber of HCC-induced tumors (  24  ). 
  The results presented by Fong et al. 
suggest that pharmacologic inhibition of 
IKK      might have unpredictable eff  ects 
in the context of infection. This ap-
proach may make macrophages better 
killers by directing them toward an M1 
phenotype, but it might simultaneously 
tumors. Thus, IKK      inhibition could 
represent a novel way to   “  re-educate  ”   
tumor- or infection-associated macro-
phages and thus promote their ability to 
eradicate abnormal cells proliferating 
within us. Evidence and intuition sug-
gest that such a therapeutic approach 
holds more promise in the realm of can-
cer than infectious diseases. 
  A fi  rst consideration is the inability 
to make small molecule IKK      inhibitors 
that are tissue specifi  c. This may be less 
of a concern for cancer intervention be-
cause IKK     /NF-     B activation is detect-
able both in neoplastic cells and in 
TAMs, and appears to underlie numer-
ous synergistic processes that promote 
cancer development, progression, vascu-
larization, and metastasis (  7, 22  ). In a 
    Figure 1.         IKK    /NF-    B signals suppress M1-type macrophage activation and promote M2-type activation.   Activation of the IKK complex (e.g., 
in response to TLR- or IL-1  –  mediated signals) leads to phosphorylation of I     B, triggering its proteasomal degradation. I     B degradation frees NF-    B  to 
translocate to the nucleus and drive the expression of proinfl  ammatory genes. In the context of tumors or infections, IKK     -induced signals can block 
STAT-1 activation, which is required for macrophages to acquire a protective M1 phenotype. Deletion of IKK      in macrophages increases STAT-1 activation 
and promotes a shift toward the M1 phenotype, with increased production of IL-12 and iNOS and enhanced clearance of tumors and bacterial infections. 
IKK    /NF-    B also induces the expression of HIF-1      during hypoxia, linking the evolutionarily ancient signaling pathways of innate immunity and the 
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lation under hypoxic conditions, and 
helps to explain the strong activation of 
HIF-1      by lipopolysaccharide and other 
bacterial stimuli even at normal oxygen 
levels. It is interesting to speculate that al-
terations in the expression of HIF-1      tar-
get genes may contribute to the changes 
in macrophage polarization that resulted 
from IKK      deletion, as reported by the 
two studies in this issue. 
  The insertion of HIF-1      into the 
mix has important implications for 
IKK     -based therapeutic concepts. HIF-
1      has already been validated as a po-
tential new target for anticancer therapy, 
as animals with reduced HIF-1      ex-
pression show decreased tumor growth, 
vascularization, and metastasis, whereas 
HIF-1      overexpression has the opposite 
eff  ect (  34  ). The promoter of the gene-
encoding vascular endothelial growth 
factor (VEGF) contains hypoxia-re-
sponsive elements and NF-     B  –  binding 
sites (  35  ), and thus IKK      inhibition may 
have a dual eff   ect by depleting the 
VEGF required for tumor angiogenesis 
and increasing the tumoricidal capabil-
ities of TAMs. However, blocking 
IKK      (and thus HIF-1     ) may also com-
promise the bactericidal capacity of 
phagocytic cells, in particular neutro-
phils, which provide the fi  rst line of im-
mune defense at necrotic or hypoxic 
foci of infection. Because of the many 
complexities involved, we should prob-
ably not hold our collective breath in 
anticipation of broadly applicable IKK    -
based antiinfective therapeutics. 
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